Vaxart Inc. has announced the receipt of substantial funding for its ongoing COVID-19 vaccine development efforts. The funding, valued at up to $460.7 million, comes under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services $(HHS)$. This initiative, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), aims to accelerate the development of next-generation COVID-19 vaccines and therapeutics. Vaxart's project is supported through the Rapid Response Partnership Vehicle (RRPV) Consortium, highlighting a collaborative effort with multiple organizations to advance innovative vaccine solutions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。